Skip to main content
Fig. 7 | Experimental Hematology & Oncology

Fig. 7

From: The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification

Fig. 7

KW-2478 had effective antitumor activity in imatinib-sensitive and imatinib-resistant CML-like mouse models. a The maximum WBC counts of mice were recorded. b, c The liver and spleen weights of mice were measured. The results are expressed as the mean ± SD. *p < 0.05, **p < 0.01. d Images of the liver and spleen are displayed. e Murine liver and spleen infiltration was analysed by HE staining. The scale bar represents 50 μm. f Cells from mouse bone marrow, liver, and spleen were stained by Wright’s stain and then photographed under a microscope. The scale bar represents 20 μm. g The expression of BCR/ABL in each tissue was detected by immunofluorescence assays. The scale bar represents 10 μm. h The expression levels of BCR/ABL and HSP90 family proteins from mouse bone marrow cells were detected by western blots. i The survival curves of mice were analysed by the Kaplan–Meier method

Back to article page